Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Brain Neoplasms
  • Drug Resistance, Neoplasm
  • Glioblastoma

abstract

  • Contrast enhanced MRI does not adequately assess disease status during bevacizumab therapy for recurrent glioblastoma (GBM). A nonenhancing tumor pattern of progression is common after treatment with bevacizumab for GBM and is correlated with worse survival. Treatments after bevacizumab failure provide only transient tumor control.

publication date

  • October 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2839807

Digital Object Identifier (DOI)

  • 10.1212/WNL.0b013e3181bc0184

PubMed ID

  • 19822869

Additional Document Info

start page

  • 1200

end page

  • 6

volume

  • 73

number

  • 15